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KEY POINTS
 Endomicroscopy is a new imaging tool for gastrointestinal endoscopy.
 Panchromoendoscopy with targeted biopsies has become the method of choice for
surveillance of patients with inflammatory bowel disease.
 Endomicroscopy can be added after chromoendoscopy to clarify whether standard
biopsies are still needed.
 This smart biopsy concept can increase the diagnostic yield of intraepithelial neoplasia
and substantially reduce the need for biopsies.
 Endomicroscopy is still mainly used for research but clinical acceptance is increasing
because of a multitude of positive studies about the diagnostic value of endomicroscopy.INTRODUCTION
Patients with long-standing extensive chronic inflammatory bowel disease (IBD) have
an increased risk to develop intraepithelial neoplasia and colitis-associated cancer
compared with the average population risk. Triggers to neoplasia are chronic inflam-
mation and sporadic adenoma.1 Thus, colonoscopic surveillance is recommended in
patients with long-lasting ulcerative colitis (left side and pancolitis) as well as Crohn’s
colitis.2 Guidelines recommend performing targeted (visible lesions) and random
biopsies. Here, 2 to 4 random biopsies every 10 cm within the colon should be per-
formed.2 Dysplastic lesions are often multifocal, flat, and difficult to detect with white
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Teubner et al428In 2003, the first randomized controlled trial3 was published evaluating lesions in the
colon according to a modified pit pattern classification after panchromoendoscopy
with methylene blue (0.1%) (pit pattern I–II, endoscopic prediction of nonneoplastic
lesions; pit pattern III–V, endoscopic prediction of neoplastic lesions). Chromoendo-
scopy made it possible to identify dysplastic lesions and to clarify the borders
between neoplastic and normal tissue. This development has led to the smart biopsy
concept, in which more targeted biopsies become possible after enhanced endos-
copy (chromoendoscopy) (Figs. 1–3). Panchromoendoscopy has become the method
of choice for endoscopic surveillance of patients with IBD (European consensus
guidelines).2
Confocal laser endomicroscopy (CLE) is a research and clinical tool that promises to
improve diagnostics and therapeutic algorithms in patients with IBD. Endomicroscopy
has been shown to be useful in dysplasia detection and differentiation of lesions to
optimize their management (differentiation between colitis-associated neoplasia, spo-
radic neoplasia, and nonneoplastic lesions) and to reduce the number of unnecessary
biopsies.4 Confocal endomicroscopy has for the first time revealed in vivo tissue
microscopy to gastroenterologists.4 Using this technology, changes in vessel, con-
nective tissue, and cellular-subcellular structures can be graduated during ongoing
colonoscopy at subcellular resolution.5,6Fig. 1. Chromoendoscopy of colorectal lesions. (A) A polypoid lesion can be identified in the
ascending colon of a 64-year-old patient who has had ulcerative colitis for 34 years. (B) Chro-
moendoscopy with methylene blue (0.1%) clarifies the mucosal pattern (pit pattern IIIL,
arrow), which predicts tubular adenoma. Endoscopic resection was performed and final
histology confirmed adenoma with low-grade intraepithelial neoplasia. (C) A sessile lesion
can also be identified. A wide cryptal opening is seen (pit pattern II) using magnification
and chromoendoscopy (D). Hyperplastic changes (nonneoplastic) could be confirmed
histologically.
Fig. 2. Colitis-associated dysplasia. (A) A flat lesion is visible using white light high-
definition colonoscopy. (B) Chromoendoscopy with methylene blue (0.1%) clarifies the
borders and surface architecture. An irregular pattern with shallow depression (type IIc,
pit pattern V) can be identified (arrow and magnified view [C]). Endoscopic resection
revealed colitis-associated early cancer (shallow infiltration of the submucosal layer).
Confocal Endomicroscopy in IBD 429Confocal endomicroscopy has been shown to decrease the need for random
biopsies because it has a high negative predictive value. Its use is often combined
with chromoendoscopy. Intravital staining is used to identify lesions and targeted
endomicroscopy is performed to clarify the need for standard biopsies. Thus, endomi-
croscopically normal-looking mucosa does not usually require further standard bi-
opsies. Neoplastic changes and regenerative tissue can readily be identified using
this method. However, detailed knowledge about the microarchitecture of the mucosa
is necessary to achieve high diagnostic yields.6,7
TECHNICAL PRINCIPLES OF CONFOCAL ENDOMICROSCOPY
The CLE technique introduced in 2004 has been developed for cellular and subcellular
imaging of the mucosal layer.5 In confocal microscopy, a low-power laser is focused
to a single point in a microscopic field of view and the same lens is used as both
condenser and objective folding the optical path, so the point of illumination coincides
with the point of detection within the specimen.6 Light emanating from that point is
focused through a pinhole to a detector and light emanating from outside the illumi-
nated spot is not detected.
Because the illumination and detection systems are at the same focal plane, they
are termed confocal.6 All detected signals from the illuminated spot are captured
and the created image is an optical section representing 1 focal plane within the exam-
ined specimen. The image of a scanned region can be constructed and digitized by
measuring the light returning to the detector from successive points, and every point
is typically scanned in a raster pattern.6
Fig. 3. Endomicroscopy in IBD. (A) Normal colonic mucosa with regular crypt (arrow) archi-
tecture can be seen. (B) Inflammatory cells can be identified within the lamina propria and
are a sign of chronic inflammatory changes. (C) Inflammatory changes and dysplastic crypts
(arrow) can be seen. The basement membrane is intact. Targeted biopsies confirmed the
presence of low-grade intraepithelial neoplasia (colitis-associated dysplasia). (D) Colitis-
associated cancer is present. Distorted glands with infiltration of malignant cells into the
lamina propria (arrow) can be identified.
Teubner et al430At present, 2 CLE-based systems are used in clinical routine and research
(Table 1)6,7:
1. In CLE, a miniaturized confocal scanner is integrated into the distal tip of a flexible
endoscope (Pentax Endomicroscopy System, Japan). A blue laser light source de-
livers an excitation wavelength of 488 nm, and light emission is detected at greater
than 505 nm.8 Successive points within the tissue are scanned in a raster pattern to
construct serial en face optical section of 475  475 mm at a user-controlled vari-
able imaging depth. Lateral resolution is 0.7 mm, and optical slice thickness is 7 mm
(axial resolution). Images on the screen approximate a 1000-fold magnification of
the tissue in vivo.8
2. The probe-based system (pCLE; Cellvizio Endomicroscopy System, Mauna Kea
Technologies, Paris, France) consists of a 1.5-mm flexible miniprobe with lateral
resolution between 3.5 mm and 1 mm, depending on the miniprobe, and axial
resolution 5.0 mm. It is compatible with the working channel of any standard
Table 1
Technical aspects of endomicroscopic systems
Endoscope Based Probe Based
Outer diameter (mm) 12.8 1.0; 2.7; 2.6a
Length (cm) 120; 180 400; 300a
Field of view (mm) 475  475 320; 240; 600 mm2a
Resolution 0.7 3.5; 1.0a
Magnification 1000 1000
Imaging plane depth (mm) 0–250 (dynamic) 40–70; 55–65; 70–130 (fixed)a
a Dependent on various probes.
Confocal Endomicroscopy in IBD 431endoscope.7,8 These probes can be fitted through the working channel of most en-
doscopes for clinical use. Image acquisition is faster with this probe (12 frames/s)
at the expense of resolution being limited by the number of fibers (30,000 single
fibers 5 pixels).
Compared with probe-based CLE, endoscopic CLE has slightly higher lateral reso-
lution (approximately 0.7 vs 1.0 mm), a larger field of view (approximately 475 vs
240 mm), and variable imaging plane depth (approximately 0–250 vs 0–65 mm). How-
ever, the miniprobe is currently the only commercially available system and it can be
used in conjunction with any standard endoscope. It is simply passed over the working
channel and endomicroscopic images at video-frame rates are obtained, which allows
a dynamic examination of the vessels and microarchitecture (12 vs 0.8–1.6 frames per
second)/14).
Endomicroscopy requires contrast agents. The most commonly used dyes are fluo-
rescein (intravenous application), acriflavine (local application), and cresyl violet (local
application).8–11
The potential of endomicroscopy is not only in vivo histology. Endomicroscopy is
also able to display and observe physiologic and pathophysiologic changes during
ongoing endoscopy. Molecular imaging also becomes possible.12 In inflammatory
bowel diseases, CLE was able to spot intramucosal bacteria within the lamina prop-
ria.13 These intramucosal bacteria are more common in patients with IBD compared
with normal controls. These new visible details might refine understanding of IBD,
because increased cell shedding is linked to increased amounts of intramucosal bac-
teria as well as a higher risk to develop a flare within 12 months.14 Most recently endo-
microscopy was used for molecular imaging; labeled antibodies (adalimumab) were
applied topically onto the affected (inflamed) mucosa in patients with Crohn’s disease.
The number of membranous TNF-alpha receptors within the mucosa could be quan-
tified and the response to biologic therapy could be predicted with high accuracy
based on the fluorescence pattern of the receptors.15
CLINICAL TRIALS
An increasing body of literature has provided evidence that supports the concept of
taking smart biopsies instead of untargeted, random specimens. Image-enhanced
endoscopy using a dye-based technique (chromoendoscopy) and endomicroscopy
are performed in combination. Chromoendoscopy provides the means for detection16
with endomicroscopy for characterization.17 The combination allows more neoplastic
lesions to be detected and they can be differentiated from nonneoplastic lesions
based on surface pattern architecture. Note that endomicroscopy of the whole
Teubner et al432gastrointestinal tract is not feasible because CLE has only a limited field of view (a
maximum of 475–475 mm). The enhanced ability of chromoendoscopy and endomi-
croscopy to discriminate between nonneoplastic lesions, sporadic adenoma (adeno-
malike mass), and colitis-associated neoplasia (dysplasia-associated lesion masses)
can potentially help to reduce the risk of colorectal cancer, lengthen surveillance inter-
vals, and reduce the number of unnecessary biopsies (see Fig. 3).2,3,15
Panchromoendoscopy with either methylene blue or indigo carmine became a valid
diagnostic tool for improving the diagnostic yield of intraepithelial neoplasia using the
SURFACE guidelines in patients with IBD.17 In the first randomized trial of endomicro-
scopy in ulcerative colitis, 153 patients with long-term ulcerative colitis who were in
clinical remission were randomly assigned at a ratio of 1:1 to undergo either conven-
tional colonoscopy or panchromoendoscopy using 0.1% methylene blue in conjunc-
tion with endomicroscopy to detect intraepithelial neoplasia or colorectal cancer.4
Chromoendoscopy was used in this study to identify lesions for CLE and compared
with standard white light endoscopy with random biopsies.
In vivo endomicroscopic prediction of the nature of lesions (neoplastic vs nonneo-
plastic) was accurate in 97.8% of lesions. In the conventional colonoscopy group, 42.2
biopsies were necessary. In the chromoendoscopy/CLE group, 3.9 biopsies per pa-
tient were sufficient, if only circumscribed lesions (by chromoendoscopy) with suspi-
cious microarchitecture (by CLE) were biopsied.4 The negative predictive value (NPV)
for mucosa with a normal appearance on CLE to not harbor intraepithelial neoplasia
was 99.1%, which reinforces the concept of taking smart biopsies instead of untar-
geted, random specimens.4
Sanduleanu and colleagues18 showed that Acriflavine-guided endomicroscopy
enables clinicians to differentiate between low-grade and high-grade intraepithelial
neoplasia. Adenoma dysplasia score reliably discriminated high-grade dysplasia
from low-grade dysplasia (accuracy, 96.7%). Interobserver agreement was high (K co-
efficients: pathologist, 0.92; endomicroscopist, 0.88). In vivo histology predicted
ex vivo data with a sensitivity of 97.3%, specificity of 92.8%, and accuracy of 95.7%.
A meta-analysis of 91 studies, of which 11 on CLE by Wanders and colleagues19
compared the pooled sensitivity, specificity, and real-time NPV of virtual chromoendo-
scopy (NBI, i-scan, FICE), CLE, and autofluorescence imaging for differentiation be-
tween neoplastic and nonneoplastic colonic lesions. This meta-analysis showed
that virtual chromoendoscopy and CLE had an overall similar sensitivity and speci-
ficity, in that CLE produced the best results (sensitivity of 93% and specificity of
89%) and only CLE had a real-time NPV of more than 90%. A further meta-analysis
of 15 studies of CLE, of which 4 on IBD by Su and colleagues20 showed the effective-
ness of CLE in discriminating between neoplastic and nonneoplastic lesions, showed
similar results in pooled sensitivity and specificity, whereby specificity was even higher
(sensitivity of 94% and specificity of 95%).THE USE OF CRESYL VIOLET AND CONFOCAL ENDOMICROSCOPY
For tissue illumination with endomicroscopic low-power laser (488-nm blue laser light)
application of fluorescence agents are necessary. Most studies in humans have been
performed with intravenous fluorescein sodium (5 mL, 10%). Fluorescein quickly dis-
tributes within all compartments of the tissue, and CLE is possible within seconds after
injection. It contrasts cellular and subcellular details, connective tissue, and vessel
architecture at high resolution, but does not stain nuclei.12
Intravenous fluorescein is a nontoxic agent that is safe andmostly well tolerated, and
only transient discoloration of the skin has been described.12 CLE with intravenous
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cells of the colonic mucosa in vivo. However, the nuclei of the intestinal epithelium
are not readily visible because of the pharmacokinetic properties of fluorescein. Acri-
flavine and cresyl violet are alternative dyes that are applied topically and highlight
nuclei, cell membranes, cytoplasm, and to a lesser extent vessels. Acriflavine accumu-
lates in nuclei and therefore carries a potential mutagenic risk. Cresyl violet, which en-
riches in the cytoplasm and visualizes nuclear morphology negatively, is an alternative.
A 2-step study approach made in 2007 by Goetz and colleagues21 evaluated the
staining characteristics and optimal concentration of a single topical contrast agent,
cresyl violet (Merck, Darmstadt, Germany) for simultaneous chromoendoscopy and
CLE for straightforward and reliable recognition of lesions and their immediate charac-
terization in vivo. After establishing the optimal cresyl violet dye concentration of
0.13% with a pH of 3.8 in an animal preclinical study, 67 sites in 36 patients in a pro-
spective clinical study were topically stained and subsurface serial images were
generated at different depths using CLE. The results showed a good resolution with
chromoendoscopy for pit pattern classification and good fluorescent contrast for
endomicroscopy. Imaging at variable penetration depths permitted high-resolution
visualization of tissue architecture and subcellular details, such as mucin in goblet
cells, and, more importantly, cell nuclei so that in vivo distinction of low-grade versus
high-grade intraepithelial neoplasia was possible for the first time. Endomicroscopic
targeting of biopsies to a region of altered nucleus/cytoplasm ratio on intravital stain-
ing with cresyl violet has resulted in the diagnosis of 1 additional case of high-grade
intraepithelial neoplasia, and the overall prediction rate of neoplastic changes by
CLE was excellent, although the small number of sites investigated may limit the
significance of this finding.21
SUMMARY
Endomicroscopy is a new imaging tool for gastrointestinal endoscopy. In vivo histol-
ogy becomes possible at subcellular resolution during ongoing colonoscopy.
Panchromoendoscopy with targeted biopsies has become the method of choice for
surveillance of patients with IBD with IBD. Endomicroscopy can be added after chro-
moendoscopy to clarify whether standard biopsies are still needed. This smart biopsy
concept can increase the diagnostic yield of intraepithelial neoplasia and substantially
reduce the need for biopsies.
Endomicroscopy is still mainly used for research but clinical acceptance is
increasing because of a multitude of positive studies about the diagnostic value of
endomicroscopy. Different contrast agents are available to identify cellular and subcel-
lular structures. Fluorescent agents can also be combined with proteins or antibodies
to enablemolecular imaging. Smart biopsies, functional imaging (eg, defining local bar-
rier dysfunction), and molecular imaging (predicting the response to biologic therapy)
may represent the future for endomicroscopy.
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